Trial Information

Summary: Dendritic/AML Fusion Cell Vaccine Therapy for AML Patients in First Remission: A Phase I Clinical Trial.

Study Description:
While many patients with AML achieve a remission with standard treatment, there is a high risk for relapse. We would like to see if a vaccine can stimulate an immune system reaction against the leukemia cells. We seek to enroll patients with newly diagnosed AML. Participants in this research study will have some of their own leukemia cells and immune stimulatory cells collected, fused together and stored to be given as a vaccine if they achieve a remission after standard treatment.

Study Criteria:

• Patients with bone-marrow biopsy confirmed diagnosis of AML .
• Patients must be at least 18 years old.
• Patients must give written informed consent in accordance with institutional and federal guidelines.
• Patients must not have received other immunotherapy treatment in the past three months.
• Patients must be without clinical evidence of CNS disease.
• Patients must not have clinically significant autoimmune disease.
• Patients must be HIV negative.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.